Table 3.

Secondary and other measures, change (week 2 − week 0)*

MeasuresBotulinum toxinPlaceboNet effect (95% CI)p Value
* All results are average values, except where indicated.
† p Value is for a t -test of Ho: μnet effect = 0 except in the case of untreated tics per minute for which a t -test was performed on the weighted net effect values in order to standardize the measures. No adjustment for multiple tests has been applied to the calculation of p values.
Shapiro = Shapiro Tourette Syndrome Severity Scale11; TS Global Score = Tourette Syndrome Global Score10; Yale = Yale Global Tic Severity Scale12; UTRS = Unified Tic Rating Scale.13
Secondary outcome
Untreated tics/min, median %−21−12−5, Interquartile range −48, 210.80
Urge (treated tic)−0.460.49−0.94 (−1.71, −0.18)0.02
Premonitory sensation (treated tic)0.070.29−0.25 (−0.91, 0.41)0.47
Shapiro (all tics)−0.28−0.300.03 (−0.86, 0.92)0.95
Other rating evaluations
TS Global Score (all tics)−2.59−1.61−0.99 (−5.18, 3.20)0.65
Yale (treated tic)
Frequency−0.54−0.34−0.12 (−0.67, 0.43)0.68
Intensity−0.59−0.09−0.78 (−1.32, −0.24)0.01
Interference−0.06−0.12−0.07 (−0.95, 1.09)0.90
UTRS suppression
Treated−0.970.12−1.17 (−14.4, 12.1)0.87
Untreated3.563.030.69 (−10.6, 12.0)0.90
UTRS interference (all tics)−4.12−3.00−2.33 (−12.0, 7.35)0.64
Pain (treated tic)0.17−0.250.5 (−0.14, 1.14)0.15